Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma

XIONG Chaogang; ZHU Yurong; AN Mengna; LI Ying; ZHANG Xin; ZHANG Shengjie; FENG Kezhen; FENG Weiyi

doi:10.6039/j.issn.1001-0408.2024.10.14

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma

更新时间：2025-09-25

- Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma
- ZHONGGUO YAOFANG Vol. 35, Issue 10, Pages: 1232-1237(2024)
- 作者机构：
  
  1.西安市胸科医院药剂科，西安　710100
  2.甘肃省妇幼保健院药学部，兰州　730050
  3.西安交通大学第一附属医院药学部，西安　710061
  4.陕西省第二人民医院临床药学部，西安　710005
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.10.14
  CLC： R956
- Received：11 September 2023，
  
  Revised：2024-04-18，
  
  Accepted：23 April 2024，
  
  Published：30 May 2024
- 稿件说明：
移动端阅览
熊朝刚,朱玉蓉,安梦娜,等.奥马珠单抗治疗重度过敏性哮喘的药物经济学评价[J].中国药房,2024,35(10):1232-1237.

XIONG Chaogang,ZHU Yurong,AN Mengna,et al.Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma[J].ZHONGGUO YAOFANG,2024,35(10):1232-1237.
熊朝刚,朱玉蓉,安梦娜,等.奥马珠单抗治疗重度过敏性哮喘的药物经济学评价[J].中国药房,2024,35(10):1232-1237. DOI： 10.6039/j.issn.1001-0408.2024.10.14.

XIONG Chaogang,ZHU Yurong,AN Mengna,et al.Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma[J].ZHONGGUO YAOFANG,2024,35(10):1232-1237. DOI： 10.6039/j.issn.1001-0408.2024.10.14.

摘要

目的

从我国医疗提供者角度出发，对奥马珠单抗治疗重度过敏性哮喘的经济性进行评价。

方法

基于一项奥马珠单抗治疗重度过敏性哮喘的国际多中心研究数据，根据重度过敏性哮喘的疾病发展进程建立Markov模型，循环周期为4周，以质量调整生命年（QALYs）和增量成本-效果比（ICER）为产出指标，模拟奥马珠单抗联合标准治疗（SoC）方案对比SoC方案治疗重度过敏性哮喘的长期健康效果与成本，并采用单因素敏感性分析、概率敏感性分析和情境分析检验结果的稳健性。

结果

与SoC方案相比，奥马珠单抗联合SoC方案的ICER为107 723.05元/QALY，小于3倍2023年我国人均国内生产总值（GDP）的意愿支付（WTP）阈值（268 074元/QALY）。单因素敏感性分析结果显示，基线血清总免疫球蛋白E水平对模型的稳健性影响最大。概率敏感性分析结果显示，在阈值为268 074元/QALY时，奥马珠单抗+SoC方案具有经济性的概率为93.00%。情境分析结果显示，真实世界中奥马珠单抗按药品规格而不按实际用量的计费方式可能会升高ICER。

结论

以3倍2023年我国人均GDP为WTP阈值时，与SoC方案相比，奥马珠单抗联合SoC方案治疗重度过敏性哮喘具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of omalizumab in the treatment of severe allergic asthma from the perspective of healthcare providers in China.

METHODS

Based on the data from an international multicenter study of omalizumab in the treatment of severe allergic asthma， the Markov model was constructed according to the progression of severe allergic asthma， with a cycle of 4 weeks. Long-term health outcomes and costs of omalizumab combined with standard of care（SoC） regimen versus SoC regimen in the treatment of severe allergic asthma were simulated by using quality-adjusted life years （QALYs） and incremental cost-effectiveness ratio（ICER） as output indexes. One-way sensitivity analysis， probabilistic sensitivity analysis， and scenario analysis were performed to test the robustness of the results.

RESULTS

Compared with the SoC regimen， ICER for the omalizumab combined with SoC regimen was 107 723.05 yuan/QALY， which was less than the willingness-to-pay（WTP） threshold （268 074 yuan/QALY） calculated by three times per capita gross domestic product（GDP） in China in 2023. The one-way sensitivity analysis showed that the baseline serum level of immunoglobulin E had the greatest impact on the robustness of the model. The probabilistic sensitivity analysis showed that the omalizumab+SoC regimen had a 93.00% probability of being cost-effective. The scenario analysis showed that in the real world， the billing method of omalizumab based on specifications rather than actual usage may increase ICER.

CONCLUSIONS

Compared with the SoC regimen， the combination of omalizumab and SoC regimen for treating severe allergic asthma is cost-effective， with a WTP threshold of three times China’s per capita GDP in 2023.

关键词

Keywords

references

TANG K ， HUANG J ， XIE S ， et al . Temporal trend in burden of asthma in China，South Korea，and Japan，1990-2019：results from the Global Burden of Disease Study 2019 [J ] . J Thorac Dis ， 2023 ， 15 （ 5 ）： 2559 - 2570 .

GBD 2019 Diseases and Injuries Collaborators . Global burden of 369 diseases and injuries in 204 countries and territories，1990-2019：a systematic analysis for the Global Burden of Disease Study 2019 [J ] . Lancet ， 2020 ， 396 （ 10258 ）： 1204 - 1222 .

HOLGATE S ， BISGAARD H ， BJERMER L ， et al . The Brussels declaration：the need for change in asthma management [J ] . Eur Respir J ， 2008 ， 32 （ 6 ）： 1433 - 1442 .

REDDEL H K ， BACHARIER L B ， BATEMAN E D ， et al . Global initiative for asthma strategy 2021：executive summary and rationale for key changes [J ] . Eur Respir J ， 2021 ， 59 （ 1 ）： 2102730 .

中华医学会呼吸病学分会哮喘学组 . 支气管哮喘防治指南：2020年版 [J ] . 中华结核和呼吸杂志， 2020 ， 43 （ 12 ）： 1023 - 1048 .

Asthma Group of Chinese Thoracic Society . Guidelines for bronchial asthma prevention and management：2020 edition [J ] . Chin J Tuberc Respir Dis ， 2020 ， 43 （ 12 ）： 1023 - 1048 .

CHENG S L . Immunologic pathophysiology and airway remodeling mechanism in severe asthma：focused on IgE-mediated pathways [J ] . Diagnostics ， 2021 ， 11 （ 1 ）： 83 .

CHIANG D T ， CLARK J ， CASALE T B . Omalizumab in asthma：approval and postapproval experience [J ] . Clin Rev Allergy Immunol ， 2005 ， 29 （ 1 ）： 3 - 16 .

BOUSQUET J ， SIERGIEJKO Z ， SWIEBOCKA E ， et al . Persistency of response to omalizumab therapy in severe allergic（IgE-mediated）asthma [J ] . Allergy ， 2011 ， 66 （ 5 ）： 671 - 678 .

SULLIVAN P W ， LI Q Y ， BILIR S P ， et al . Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States [J ] . Curr Med Res Opin ， 2020 ， 36 （ 1 ）： 23 - 32 .

王李婷，彭六保，彭烨，等 . 2020年版和2011年版中国药物经济学评价指南比较分析 [J ] . 中国药物经济学， 2021 ， 16 （ 3 ）： 5 - 8，15 .

WANG L T ， PENG L B ， PENG Y ， et al . Comparative analysis between 2020 version and 2011 version on China guidelines for pharmacoeconomic evaluation [J ] . China J Pharm Econ ， 2021 ， 16 （ 3 ）： 5 - 8，15 .

CASALE T B ， LUSKIN A T ， BUSSE W ， et al . Omalizumab effectiveness by biomarker status in patients with asthma：evidence from PROSPERO，a prospective real-world study [J ] . J Allergy Clin Immunol Pract ， 2019 ， 7 （ 1 ）： 156 - 164.e1 .

FLEURENCE R L ， HOLLENBEAK C S . Rates and pro-babilities in economic modelling：transformation，translation and appropriate application [J ] . Pharmacoeconomics ， 2007 ， 25 （ 1 ）： 3 - 6 .

国务院人口普查办公室 . 2010年全国第六次人口普查报告 [R/OL ] .（ 2011-04-28 ）[ 2023-10-09 ] . https：//www.stats.gov.cn/english/Statisticaldata/CensusData/rkpc2010/indexch.htm https://www.stats.gov.cn/english/Statisticaldata/CensusData/rkpc2010/indexch.htm .

Population Census Office under the State Council . Tabulation on the 2010 population census of the People’s Republic of China 2010 [R/OL ] .（ 2011-04-28 ）[ 2023-10-09 ] . https：//www.stats.gov.cn/english/Statisticaldata/CensusData/rkpc2010/indexch.htm https://www.stats.gov.cn/english/Statisticaldata/CensusData/rkpc2010/indexch.htm .

HUANG G M ， LIU J T ， LI T ， et al . Long-term trends of asthma mortality in China from 2000 to 2019：a joinpoint regression and age-period-cohort analysis [J ] . Healthcare ， 2022 ， 10 （ 2 ）： 346 .

LIN J T ， XING B ， TANG H P ， et al . Hospitalization due to asthma exacerbation：a China asthma research network（CARN）retrospective study in 29 provinces across mainland China [J ] . Allergy Asthma Immunol Res ， 2020 ， 12 （ 3 ）： 485 - 495 .

胡俊华，张艳霞，胡艳秋，等 . 不同剂量吸入性皮质类固醇联合长效β 2 激动剂治疗成人持续性哮喘患者的效果及成本-效益分析 [J ] . 中国药物滥用防治杂志， 2022 ， 28 （ 6 ）： 736 - 739，744 .

HU J H ， ZHANG Y X ， HU Y Q ， et al . Immune function and cost-benefit analysis of different doses of inhaled corticosteroids combined with long-acting β 2 agonists in the treatment of adult persistent asthma [J ] . Chin J Drug Abuse Prev Treat ， 2022 ， 28 （ 6 ）： 736 - 739，744 .

ZHANG M ， JIN M L ， ZHOU X ， et al . Effectiveness of omalizumab in patients with severe allergic asthma：a retrospective study in China [J ] . Respir Med ， 2021 ， 186 ： 106522 .

ALANGARI A A . Corticosteroids in the treatment of acute asthma [J ] . Ann Thorac Med ， 2014 ， 9 （ 4 ）： 187 - 192 .

郭平平，鲁丽杰，崔琦 . 急诊救护临床护理路径在哮喘患者中的应用效果 [J ] . 黑龙江中医药， 2019 ， 48 （ 4 ）： 315 - 316 .

GUO P P ， LU L J ， CUI Q . Application effect of clinical nursing pathway of emergency rescue in asthma patients [J ] . Heilongjiang J Tradit Chin Med ， 2019 ， 48 （ 4 ）： 315 - 316 .

林江涛，邢斌，唐华平，等 . 2013—2014年我国城区支气管哮喘急性发作住院患者的临床特征及住院费用的回顾性调查 [J ] . 中华结核和呼吸杂志， 2017 ， 40 （ 11 ）： 830 - 834 .

LIN J T ， XING B ， TANG H P ， et al . A multi-center retrospective study of clinical characteristics and hospitalization costs of patients hospitalized for asthma exacerbation in China during 2013-2014 [J ] . Chin J Tuberc Respir Dis ， 2017 ， 40 （ 11 ）： 830 - 834 .

LLOYD A ， PRICE D ， BROWN R . The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK [J ] . Prim Care Respir J ， 2007 ， 16 （ 1 ）： 22 - 27 .

MCQUEEN R B ， SHEEHAN D N ， WHITTINGTON M D ， et al . Cost-effectiveness of biological asthma treatments：a systematic review and recommendations for future economic evaluations [J ] . Pharmacoeconomics ， 2018 ， 36 （ 8 ）： 957 - 971 .

TUGAY D ， TOP M ， AYDIN Ö ， et al . Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey [J ] . J Med Econ ， 2023 ， 26 （ 1 ）： 720 - 730 .

ZHOU H ， LU Y M ， WU B ， et al . Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children [J ] . J Asthma ， 2020 ， 57 （ 1 ）： 87 - 94 .

CAI D ， SHI S ， JIANG S ， et al . Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life [J ] . Eur J Health Econ ， 2022 ， 23 （ 4 ）： 607 - 615 .

OCHALEK J ， WANG H Y ， GU Y Y ， et al . Informing a cost-effectiveness threshold for health technology assessment in China：a marginal productivity approach [J ] . Pharmacoeconomics ， 2020 ， 38 （ 12 ）： 1319 - 1331 .

LI J ， KANG J ， WANG C Z ， et al . Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma：a randomized phase Ⅲ study [J ] . Allergy Asthma Immunol Res ， 2016 ， 8 （ 4 ）： 319 - 328 .

LI N ， CAO L F ， ZHANG M ， et al . Response to omalizumab as an add-on therapy in the treatment of allergic asthma in adult Chinese patients：a retrospective study [J ] . Vaccines ， 2022 ， 10 （ 12 ）： 2068 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy

Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer

Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer

Cost-utility analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma with high PD-L1 expression

Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate- to high-risk non-muscle invasive bladder cancer in China

Related Author

XIA Runan

DI Panpan

ZHAO Mengmeng

ZHANG Pengcheng

HOU Yashen

ZHANG Hong

WU Wei

LIANG Hai

Related Institution

Dept. of Pharmacy， the People’s Hospital of Bozhou

Health Economics and Promotion Research Center， Guangdong Pharmaceutical University

International Research Center for Medicinal Administration， Peking University

School of Pharmaceutical Sciences， Peking University

School of Medical Business， Guangdong Pharmaceutical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰